In a unanimous vote, 17-0, a panel of advisers to the Meals and Drug Administration beneficial that the company approve the primary over-the-counter contraception tablet.
If permitted, the tablet can be offered by Perrigo beneath the model title Opill. It’s a so-called progestin-only tablet that comprises solely an artificial model of the hormone progesterone to stop being pregnant. Most tablets additionally include estrogen. Whereas the FDA usually follows the advice of its advisory committees, it is not required to.
In feedback after the vote, panel members defined their assist for the prescription-free tablet.
“I really feel that the danger of unintended being pregnant is decrease with this strategy than any of the opposite out there contraceptive approaches that ladies have entry to with out seeing a well being care supplier,” mentioned Dr. Deborah Armstrong, a professor of oncology, gynecology and obstetrics at Johns Hopkins. She added that she thought individuals would be capable to understood if any well being situations they’ve can be incompatible with taking the tablet.
“I voted sure as a result of the proof demonstrates that the advantages clearly exceed the dangers,” mentioned Kathryn Curtis, a well being scientist with the Facilities for Illness Management and Prevention’s division of reproductive well being. The advantages embrace elevated entry to efficient contraception, discount in unintended pregnancies and its dangers and elevated reproductive autonomy. “Opill has the potential to have an enormous public well being impression,” she mentioned.